Symbyax: Difference between revisions

(2 intermediate revisions by the same user not shown)

Line 15:

| bioavailability = Olanzapine 60% (oral); fluoxetine high (oral)<ref name="symbyax-label" />

| pregnancy = Limited data; fluoxetine has reassuring data but olanzapine carries metabolic-syndrome and gestational diabetes signals.{{citation needed}}

| legal = [[USLegal:Prescription only|Rx-only]] in US. Carries the '''antidepressant Boxed Warning''' for suicidality in children/adolescents/young adults and the atypical-~~antipsychotic~~ '''Boxed Warning''' for increased mortality in elderly dementia patients<ref name="symbyax-label" />

| legal = [[USLegal:Prescription only|Rx-only]] in US. Carries the '''antidepressant Boxed Warning''' for suicidality in children/adolescents/young adults and the atypical-neuroleptic '''Boxed Warning''' for increased mortality in elderly dementia patients<ref name="symbyax-label" />

| mechanism = <vote slug="symbyax-mech-claim">Olanzapine is a thienobenzodiazepine atypical neuroleptic with D2, 5-HT2A/2C, H1, M1, and α1 antagonism, providing both antimanic effect and adjunctive mood-stabilization. Fluoxetine is a selective serotonin reuptake inhibitor with antidepressant effect. The combination addresses the dual challenge of bipolar depression — risk of antidepressant-induced manic switch and inadequate response to mood stabilizer monotherapy — by pairing the fluoxetine antidepressant with the olanzapine mood-stabilizing/antimanic anchor.</vote> Metabolic effects (weight gain, dyslipidemia, glucose dysregulation) dominate the long-term tolerability profile; routine metabolic monitoring is standard<ref name="symbyax-label" />.

| mechanism = <vote slug="symbyax-mech-claim">Olanzapine is a thienobenzodiazepine atypical neuroleptic with D2, 5-HT2A/2C, H1, M1, and α1 antagonism, providing both antimanic effect and adjunctive mood-stabilization. Fluoxetine is a selective serotonin reuptake inhibitor with antidepressant effect. The combination addresses the dual challenge of bipolar depression, risk of antidepressant-induced manic switch and inadequate response to mood stabilizer monotherapy, by pairing the fluoxetine antidepressant with the olanzapine mood-stabilizing/antimanic anchor.</vote> Metabolic effects (weight gain, dyslipidemia, glucose dysregulation) dominate the long-term tolerability profile; routine metabolic monitoring is standard<ref name="symbyax-label" />.

}}

== References ==

[[Category:Neuroleptics]]

[[Category:Antidepressants]]

[[Category:Mood stabilizers]]

[[Category:Fixed-dose combinations]]

MDElliottMD (talk | contribs)